Summary
The provided AI claims include multiple non-label items (patient assistance/copoly/savings program eligibility and benefits) and label-misaligned phrasing that is not fully supported by the supplied FDA label excerpts. The indication statements omit key label constraints (statin-adjunct, TG threshold, and CV risk-factor criteria), so they cannot be considered on-label accurate.
Category Scores
Accurate Statements
Vascepa is a prescription medication used to treat high triglycerides.
Supported only in the broad sense that the label includes use to reduce triglycerides (Section 1: adjunct to diet to reduce TG levels in severe hypertriglyceridemia).
Unsupported Statements
Vascepa is used to reduce the risk of heart attack and stroke in patients with high triglycerides and established cardiovascular disease.
Label indication for cardiovascular risk reduction is as an adjunct to maximally tolerated statin therapy and includes specific criteria: elevated TG (≥150 mg/dL) plus established cardiovascular disease OR diabetes mellitus with 2 or more additional cardiovascular risk factors; the claim does not include these required constraints (Section 1).
The Patient Assistance Program (PAP) for Vascepa provides free Vascepa to eligible patients who are uninsured or underinsured.
No patient assistance program terms are present in the supplied prescribing information excerpts; this is not supported by the provided label text.
Eligibility for Vascepa PAP requires annual income of $100,000 or less for individuals and $150,000 or less for families.
No PAP income eligibility criteria are present in the supplied prescribing information excerpts.
The Copay Program for Vascepa provides a $10 copay for eligible patients who are insured.
No copay program details or dollar amount are present in the supplied prescribing information excerpts.
Eligibility for the Vascepa Copay Program requires annual income of $100,000 or less for individuals and $150,000 or less for families.
No copay program income eligibility criteria are present in the supplied prescribing information excerpts.
The Vascepa Savings Program provides discounts on Vascepa for eligible patients.
No savings/discount program description is present in the supplied prescribing information excerpts.
Eligibility for the Vascepa Savings Program requires annual income of $100,000 or less for individuals and $150,000 or less for families.
No savings program income eligibility criteria are present in the supplied prescribing information excerpts.
The National Lipid Association's Patient Assistance Program provides free Vascepa to eligible patients who are uninsured or underinsured.
No National Lipid Association PAP terms are present in the supplied prescribing information excerpts.
Eligibility for the National Lipid Association Patient Assistance Program requires maximum annual income of $50,000 or less for individuals and $75,000 or less for families.
No National Lipid Association PAP income criteria are present in the supplied prescribing information excerpts.
Contradictions
Important Omissions
For cardiovascular risk reduction, the claim omits key label requirements: adjunct to maximally tolerated statin therapy; elevated triglycerides (≥150 mg/dL); and patient population definition (established CVD OR diabetes mellitus with 2 or more additional CV risk factors).
Importance:
High
For triglyceride-lowering use, the claim does not specify that the TG-lowering indication is as an adjunct to diet for severe hypertriglyceridemia (≥500 mg/dL), nor does it address the label’s limitation of pancreatitis risk uncertainty.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
Inaccurate/insufficiently specified on-label indication (CV risk reduction) could lead to inappropriate framing of who should receive Vascepa; patient assistance program claims are not supported by the supplied FDA label and therefore may mislead regarding access/eligibility.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Multiple claims about PAP/copay/savings programs and eligibility/income thresholds are not present in the provided FDA label excerpts; the cardiovascular indication claim omits essential label constraints.
Suggested Improvement
Limit claims to the supplied label language and include required indication constraints (statin-adjunct; TG ≥150 mg/dL; established CVD OR diabetes with ≥2 additional CV risk factors). Remove or refrain from stating PAP/copay/savings program benefits, eligibility, and income thresholds unless those details are explicitly provided in the FDA label excerpts (not included here).